• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Turkey Pharmaceuticals and Healthcare Report Q2 2012 - Product Image

Turkey Pharmaceuticals and Healthcare Report Q2 2012

  • Published: February 2012
  • Region: Turkey
  • 107 Pages
  • Business Monitor International

FEATURED COMPANIES

  • Abdi Ibrahim
  • Bayer
  • Fako (Actavis)
  • Merck & Co
  • Pfizer
  • Sanofi
  • MORE

Business Monitor International's Turkey Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Turkey's pharmaceuticals and healthcare industry.

BMI View:

While the Turkish pharmaceutical industry has achieved some concessions following additional price cuts and public discounts announced in November 2011, the impact of the November decree remains negative. That aside, BMI emphasises that the number-one concern for drugmakers in 2012 should be lira weakness. BMI's Country Risk team have further revised down our expectations for the lira in 2012. With publicly purchased drug prices tied to a historic lira/euro exchange rate, there is no way drugmakers can raise prices to offset the weakness of the local currency and ensure stable repatriated revenues. This means global drugmakers in Turkey are completely exposed to lira weakness and this will add to the list of challenges already faced by the industry.

Headline Expenditure Projections

.. Pharmaceuticals: TRY17.44bn (US$10.48bn) READ MORE >

Executive Summary
SWOT Analysis
Turkey Pharmaceuticals And Healthcare Industry SWOT
Turkey Political SWOT
Turkey Economic SWOT
Turkey Business Environment SWOT
Pharmaceuticals & Healthcare Risk/Reward Ratings
Table: Central And Eastern Europe Pharmaceuticals & Healthcare Risk/Reward Ratings (RRRs), Q212
Rewards
Risks
Turkey – Market Summary
Regulatory Regime
Intellectual Property Regime
Market Access Issues
Pricing Regime
Table: Turkish Pharmaceutical Pricing Decrees
Drug Price Inflation
Reimbursement Regime
Table: Pharmacist discount related to annual sales revenue (VAT excluded) .
Industry Developments
Epidemiology
Non-Communicable Diseases
Healthcare Sector
Healthcare Infrastructure
Research & Development
Clinical Trials Industry
Medical Devices Industry
Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2008-2016
Healthcare Market Forecasts
Table: Healthcare Expenditure Indicators 2008-2016
Table: Healthcare Governmental Indicators 2008-2016
Table: Healthcare Private Indicators 2008-2016
Key Growth Factors – Macroeconomic
Table: Turkey – Economic Activity
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2008-2016
Patented Drug Market Forecast
Table: Patented Drug Market Indicators 2008-2016
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2008-2016
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2008-2016
Medical Device Market Forecast
Table: Medical Devices Sales Indicators 2008-2016
Pharmaceutical Trade Forecast
Table: Exports and Imports Indicators 2008-2016
Key Risks To BMI’s Forecasts
Competitive Landscape
Pharmaceutical Sector
Domestic Industry
Foreign Industry
Company Activity
Company Profiles
Local Companies
Abdi Ibrahim
Eczacibasi Pharmaceuticals
Sanovel Pharmaceuticals
Deva (EastPharma)
Fako (Actavis)
Mustafa Nevzat Ilac Sanayi (MN) Pharmaceuticals
Multinational Companies
Novartis
Pfizer
Sanofi
GlaxoSmithKline
Roche
AstraZeneca
Bayer
Merck & Co
Country Snapshot: Turkey Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Glossary
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources

- Abdi Ibrahim
- Eczacibasi Pharmaceuticals
- Sanovel Pharmaceuticals
- Deva (EastPharma)
- Fako (Actavis)
- Mustafa Nevzat Ilac Sanayi (MN) Pharmaceuticals
- Novartis
- Pfizer
- Sanofi
- GlaxoSmithKline
- Roche
- AstraZeneca
- Bayer
- Merck & Co

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos